Evolutionary Genomics, Inc. Share Price

Equities

FNAM

US30051F1012

Biotechnology & Medical Research

Market Closed - OTC Markets 20:26:12 18/07/2023 BST 5-day change 1st Jan Change
0.45 USD -25.00% Intraday chart for Evolutionary Genomics, Inc. -.--% -.--%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2021 - Sales 2022 - Capitalization 4.66M 365M
Net income 2021 -2M -157M Net income 2022 -1M -78.32M EV / Sales 2021 -
Net Debt 2021 3.53M 276M Net Debt 2022 3.17M 248M EV / Sales 2022 -
P/E ratio 2021
-1.34 x
P/E ratio 2022
-2 x
Employees 3
Yield 2021 *
-
Yield 2022
-
Free-Float 67.35%
More Fundamentals * Assessed data
Dynamic Chart
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Evolutionary Genomics, Inc. announced that it has received $1.004004 million in funding CI
Evolutionary Genomics, Inc. announced that it expects to receive $1.004004 million in funding CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
Evolutionary Genomics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020 CI
More news
1 year
0.45
Extreme 0.45
0.70
3 years
0.45
Extreme 0.45
1.39
5 years
0.45
Extreme 0.45
5.71
10 years
0.10
Extreme 0.1
5.71
More quotes
Managers TitleAgeSince
Founder 69 31/10/90
Chief Executive Officer 68 31/08/10
Members of the board TitleAgeSince
Chief Executive Officer 68 31/08/10
Director/Board Member 64 31/12/09
Founder 74 31/10/90
More insiders
Evolutionary Genomics, Inc. is a genomics research and development company. The Company is focused on the identification and validation of genes that impact commercially traits in crops for the agriculture industry. It uses the Adapted Traits Platform (ATP) to identify commercially valuable genes that control important traits in animals and plants. Its platform identifies genes that have changed successfully to impart new or improved traits. The Company has applied its ATP in research projects, including identifying genes responsible for increases in yield in corn, increases in yield in rice, drought tolerance and sugar content in tomatoes and pest/disease resistance in soybeans, cassava, beans, tomatoes, and cotton. The Company uses ATP to perform throughput molecular evolution analysis to identify positively selected genes based on non-synonymous site (Ka) and synonymous site (Ks) analysis.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW